Patients with EGFR-mutant pulmonary adenocarcinoma have been found to have a higher proportion of synchronous liver metastasis (LM) than those with EGFR wild-type tumor, and patients with an adequate performance status and ≤5 LM nodules could be considered for systemic therapy combined with radiofrequency ablation when LM develops [48]. Here, EGFR is linked to lymphangioma.